0      0

JL1110ES - JL1110ES: EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting.

‐ Oct 24, 2023 12:00am

Aditya Bardia, MD;1 Francois-Clement Bidard, MD, PhD;2 Patrick Neven, MD, PhD;3 Guillermo Streich, MD;4 Alberto J. Montero, MD, MBA, CPHQ;5 Frederic Forget,MD;6 Marie-Ange Mouret-Reynier,MD;7 Joo Hyuk Sohn, MD, PhD;8 Donatienne Taylor, MD;9 Kathleen K. Harnden, MD;10 Hung Khong, MD;11 Judit Kocsis, MD, PhD;12 Florence Dalenc, MD, PhD;13 Patrick M. Dillon, MD;14 Sunil Babu, MD;15 Simon Waters, MD, PhD;16 Ines Deleu, MD;17 Jose A. Garcia-Saenz J, MD, PhD;18 Emilio Bria, MD;19 Marina Elena Cazzaniga,20 Phillipe Aftimos, MD;21 Javier Cortes, MD, PhD;22 Giulia Tonini;23 Tarek Sahmoud, MD, PhD;24 Nassir Habboubi, MD;24 Krzysztof J. Grzegorzewski,MD;24 Virginia Kaklamani, MD25

1. Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA; 2. Institut Curie, Paris and Saint Cloud, France 3. Universitaire Ziekenhuizen (UZ) - Leuven Cancer Institute, Leuven, Belgium; 4. Centro Médico Austral, Buenos Aires, Argentina; 5. University Hospitals Seidman Cancer Center- Case Western Reserve University, Cleveland, OH, USA; 6. Centre Hospitalier de l'Ardenne - Site de Libramont, Libramont-Chevigny, Belgium; 7. Centre Jean Perrin, Clermont-Ferrand, France; 8. Yonsei Cancer Center, Yonsei University Health System -Medical Oncology, Seoul, Republic of Korea; Universite catholique de Louvain, CHU UCL Namur—Site Sainte-Elisabeth, Namur, Belgium; 10. Inova Schar Cancer Institute, Fairfax, Virginia; 11. Moffit Cancer Center & Research Institute, Tampa, FL, USA; 12. Bács-Kiskun Megyei Kórház, Kecskemét, Hungary; 13. Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France; 14. University of Virginia Cancer Center, Charlottesville, VA, USA; 15. Fort Wayne Medical Oncology and Hematology, Fort Wayne, IN; 16. Velindre Cancer Centre, Cardiff, UK; 17. AZ Nikolaas, Sint-Niklaas, Belgium; 18. Instituto de Investigación Sanitaria Hospital Clinico San Carlos (IdISSC), Madrid, Spain; 19. Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy; 20. Ospedale San Gerardo-ASST Monza, Monza, Italy; 21. Institut Jules Bordet – Université Libre de Bruxelles, Brussels, Belgium; 22. International Breast Cancer Center (IBCC), Quiron Group, Barcelona Spain; 23. Menarini Group, Florence, Italy; 24. Stemline Therapeutics/Menarini Group, New York, NY, USA; 25. University of Texas Health Sciences Center, San Antonio, TX.


You must be logged in and own this session in order to post comments.